Takeda to Start Clinical Trials of Covid-19 Plasma Therapy

The transcript discusses the impact of COVID-19 on the pharmaceutical industry, focusing on life-saving medicines and treatments for diseases like Crohn's. It highlights the development of plasma therapy for COVID-19, emphasizing the need for donor participation and the challenges in scaling up production. The conversation also covers supply chain stability, risk management, and the shift towards remote work and virtual operations. Insights into vaccine development and the potential for increased protectionism in supply chains are also provided.

What impact do you foresee COVID-19 having on the treatment of severe diseases?

How do you assess the short-term and long-term effects of COVID-19 on your product portfolio?

What challenges do you face in sourcing plasma from recovered COVID-19 patients?

What are the signs that indicate potential issues in your supply chain due to COVID-19?

What factors influence the scalability of vaccine manufacturing?

How has your company adapted its workforce structure in response to the pandemic?

In what ways do you think the pandemic will change the future of work in your industry?